Stay updated on Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Sign up to get notified when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.

Latest updates to the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page
- Check7 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3.SummaryDifference0.2%

- Check14 days agoChange DetectedNo additions or deletions were detected between the two screenshots.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedRevision: v3.4.2 added; the lapse-in-government-funding notice was removed; no changes to trial content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check43 days agoChange DetectedAdded a site-wide notice about government funding delays and updated the page revision to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check50 days agoChange DetectedAdded a 'Show glossary' toggle and updated labels and revision information (capitalization changes for QC-related fields; Revision: v3.4.0, replacing v3.3.4).SummaryDifference0.2%

- Check57 days agoChange DetectedCore study details such as eligibility criteria, outcomes, and treatment arms remain unchanged. The observed differences are minor formatting and wording edits.SummaryDifference0.1%

Stay in the know with updates to Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Phase II Nivolumab Plus Ipilimumab in Sarcoma & Endometrial Clinical Trial page.